Uveítis recurrentes y tratamiento con anticuerpos monoclonales (Daclizumab)

  1. ML Hernández Garfella
  2. M Díaz Llopis
  3. D Salom Alonso
  4. E Cervera Taulet
Aldizkaria:
Archivos de la Sociedad Española de Oftalmologia

ISSN: 0365-6691

Argitalpen urtea: 2004

Alea: 79

Zenbakia: 12

Orrialdeak: 593-598

Mota: Artikulua

DOI: 10.4321/S0365-66912004001200004 DIALNET GOOGLE SCHOLAR lock_openSarbide irekia editor

Beste argitalpen batzuk: Archivos de la Sociedad Española de Oftalmologia

Objetivos de desarrollo sostenible

Laburpena

Purpose: Assess the efficacy of monoclonal antibody (daclizumab) therapy in the treatment of patients with non-infectious uveitis who do not respond to other immunosuppressive agents. Material and method: Ten patients with non-infectious intermediate and posterior uveitis were treated with intravenous daclizumab (humanized anti-IL-2 receptor monoclonal antibody) monthly for two years. Results: 70% of the patients have had some improvement in their inflammatory activity being maintained without recurrence. 10% of the patients improved their visual acuity in two lines and the macular edema decreased. 20% of the patients continued to have recurrences, but not worse than the year before. 40% of the patients gave up having the treatment with corticosteroids and 30% with minimum dose (5 mg). No secondary effects were noted during the treatment. Conclusions: Daclizumab is effective and safe for long-term use in the treatment of uveitis which cannot be kept under control by other treatments. In time, it allows the dose of corticosteroids to be decreased or even discontinued.

Erreferentzia bibliografikoak

  • Carswell, CI, Plosker, GL, Wagstaff, AJ.. (2001). Daclizumab: a review of its use in the management of organ transplantation. BioDrugs. 15. 745-773
  • Nussenblatt, RB, Schiffman, R, Fortin, E, Robinson, M, Smith, J, Rizzo, L. (1998). Strategies for the treatment of intraocular inflammatory disease. Transplant Proc. 30. 4124-4125
  • Foster, CS, Vitale, AT.. (2002). Diagnosis and treatment of uveitis. W. B. Saunders Company. Philadelphia.
  • Bumgardner, GL, Ramos, E, Lin, A, Vincenti, F. (2001). Daclizumab Triple Therapy and Double Therapy Groups (humanized anti-IL2R alpha mAB) prophylaxis for prevention of acute rejection in renal transplant recipients with delayed graft function. Transplantation. 72. 642-647
  • Salzmann, J, Lightman, S.. (2000). The potential of newer immunomodulating drugs in the treatment of uveitis: A review. BioDrugs. 13. 397-408
  • Bruce, DS, Sollinger, HW, Humar, A, Sutherland, DE, Light, JA, Kaufman, DB. (2001). Multicenter survey of daclizumab induction in simultaneous kidney-pancreas transplant recipients. Transplantation. 72. 1637-1643
  • Egan, CA, Brown, M, White, JD, Yancey, KB.. (2001). Treatment of epidermolysis bullosa acquisita with the humanized anti-Tac mAb daclizumab. Clin Immunol. 101. 146-151
  • Nussenblatt, RB, Fortin, E, Schiffman, R, Rizzo, L, Smith, J, Van Veldhuisen, P. (1999). Treatment of noninfectious intermediate and posterior uveitis with the humanized anti- Tac mAb: a phase I/II clinical trial. Proc Natl Acad Sci USA. 96. 7462-7466
Datuen iturria: Dialnet